Skip to main content

Dinara Makenbaeva, MD, MBA

Authored Items
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
David Campbell, PharmD, MS, James T. Kenney, RPh, MBA, Marlo Blazer, PharmD, BCOP, Lisa M. Bloudek, PharmD, MS, John Brokars, MS, Dinara Makenbaeva, MD, MBA
November 2019 Vol 12, No 7 in Original Research, Practice Management
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
Lisa M. Bloudek, PharmD, MS, Gary Branning, MBA, Dinara Makenbaeva, MD, MBA, Michael Eaddy, PharmD, PhD
December 2015 Vol 8, No 9 in Original Research, Practice Management
Last modified: December 9, 2019